Fox Business - The Power to Prosper
Search Site

Abbott Laboratories

Will the markets end the year flat despite the volatility?

Glenmede Director of Investment Strategy Jason Pride, iSectors CIO Chuck Self and founder Mark Sebastian on the outlook for the markets.

Read More

  1. Stocks to watch: CVS, ABT

    Kanaly Trust Chairman Drew Kanaly, Royal Oak Financial Group Managing Partner Matt Jehn and SFG Alternatives CIO Larry Shover on the opportunities in the markets for investors.

  2. Stocks to watch: KMI, ABT

    Glenmede Director of Investment Strategy Jason Pride, Wall Financial Group’s Michael Wall and founder Mark Sebastian on where the opportunities are for investors.

  3. Stocks to watch: GOOGL, DOW

    Rosenthal Wealth Management Group President Larry Rosenthal, Platinum Partners President Uri Landesman and Tethys Partners Chief Market Strategist Bob Iaccino on the markets.

  4. Sell in May and go away?

    BlackRock chief investment strategist Russ Koesterich and Bianco Research president Jim Bianco on the state of the markets.

  5. Where should investors put their money to work?

    STA Wealth Management Chief Strategist Lance Roberts, USAA Investments V.P. John Toohey and Athena Advisor Services’ Dan Stecich on the outlook for the markets.

  6. Abbott Laboratories 1Q earnings

    Earnings HQ: FBN’s Jo Ling Kent breaks down Abbott Laboratories ’ first-quarter earnings report.

  7. Abbott Beats Profit Forecast, But Sales Lag

    Abbott Laboratories Inc reported better-than-expected quarterly earnings, but sales came in slightly below Wall Street expectations.The company on Wednesday said it ...

  8. Stocks to watch: MSFT, ABT

    Glenmede Director of Investment Strategy Jason Pride, Janney Capital Markets Technical Research Director Dan Wantrobski and Altimus Capital Director of Portfolio Management Chris Gersch on the stocks to boost investors’ portfolios.

  9. Novartis CEO Reshapes Firm For 'Brutal' New World

    Novartis Chief Executive Joe Jimenez is taking a hard look at the drugmaker's smaller businesses as he reshapes the company for what he expects to be a "brutal" new ...

  10. Dan Loeb Takes Stakes In BlackBerry, T-Mobile

    Third Point, headed by billionaire fund manager Dan Loeb, has put more money into struggling mobile device makers. According to a 13-f filing released late Friday by...

  11. Abbott Misses Top Line Views in the Fourth Quarter

    Abbott Laboratories Inc reported weaker-than-expected fourth-quarter revenue, hurt by the stronger dollar and an overseas sales disruption last summer of its baby fo...

  12. AbbVie beats forecast as Humira sales surge

    AbbVie Inc on Friday reported stronger-than-expected results for the third quarter, as booming sales of its Humira arthritis treatment and Synthroid thyroid replacem...

  1. Mylan CEO on generic drug industry, the FDA

    Mylan CEO Heather Bresch discusses the company’s impact on the health care industry, its deal with Abbott Laboratories , future developments and the FDA.

  2. What’s driving market action?

    Glenmede Director of Investment Strategy Jason Pride and Teddy Weisberg of Seaport Securities discuss the state of the markets and where to invest.

  3. Despite volatility, Trinity Industries a way to gain from rail industry?

    FBN’s Charles Payne, Stifel Nicolaus Portfolio Manager Chad Morganlander and Penn Financial Group founder Matt McCall on the outlook for Trinity Industries.

  4. UK Trade Minister talks taxes

    UK Min. of State for Trade & Investment Lord Ian Livingston on the country’s plan to attract U.S. and foreign business.

  5. Treasury takes aim at corporate inversion

    FBN’s Liz MacDonald on deal stocks under pressure as the U.S. announces stricter tax rules.

  6. Political implications of the AbbVie-Shire deal

    Chapwood Investments’ Ed Butowsky and The Wall Street Journal Editorial Board’s Mary Kissel discuss the significance of AbbVie’s purchase of Ireland’s Shire.

  7. Abbott Laboratories 2Q earnings beat expectations

    Earnings HQ: FBN’s Adam Shapiro breaks down U.S. Bancorp’s second-quarter earnings report.

‹ Prev12345Next ›
Freebase CC-BY
Source: Abbott Laboratories on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL